NCT00585910View on ClinicalTrials.gov

Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD

PHASE4CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
ADHDAttention Deficit Hyperactivity Disorder
Interventions
DRUG

Atomoxetine and OROS Methylphenidate

Subjects must have at least attempted to tolerate a dose of 1.2 mg/kg of atomoxetine. If tolerated, they must remain on this dose for at least two weeks. OROS methylphenidate will be target dosed and titrated to a maximum dose of 54 mg.

Trial Locations (1)

02138

Massachusetts General Hospital, Cambridge

All Listed Sponsors
collaborator

Ortho-McNeil Janssen Scientific Affairs, LLC

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT00585910 - Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD | Biotech Hunter | Biotech Hunter